Publisher of the most cited open-access journals in their fields.
Frontiers in Oncology is an international open-access journal that aims at publishing the best research across the entire field of oncology. The journal welcomes outstanding contributions in any domain of cancer research: from basic laboratory research to clinical investigation, from prevention to treatment, and from imaging studies to novel treatment strategies.
Frontiers in Oncology is a member of the Committee on Publication Ethics.
Short Name: Front. Oncol.
Electronic ISSN: 2234-943X
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS)
PMCID: all published articles receive a PMCID
Frontiers in Oncology is composed of the following Specialty Sections:
The specialty sections of Frontiers in Oncology welcome submission of the following article types: Book Review, Case Report, Clinical Trial, Correction, Data Report, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Technology Report, Protocols, Clinical Study Protocol and Classification.
When submitting a manuscript to Frontiers in Oncology, authors must submit the material directly to one of the specialty sections. Manuscripts are peer-reviewed by the Associate and Review Editors of the respective specialty section.
Articles published in the specialty sections above will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in the Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.